Rituximab in Membranous Nephropathy

Gauckler, Philipp, Shin, Jae Il, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, Martin, Cheung, Chee Kay, Crnogorac, Matija, Delbarba, Elisa, Eller, Kathrin, Faguer, Stanislas, Galesic, Kresimir, Griffin, Siân, van den Hoogen, Martijn W. F., Hrušková, Zdenka, Jeyabalan, Anushya, Karras, Alexandre, King, Catherine, Singh Kohli, Harbir, Mayer, Gert, Maas, Rutger, Muto, Masahiro, Moiseev, Sergey, Odler, Balazs, Pepper, Ruth J., Quintana, Luis F., Radhakrishnan, Jai, Ramachandran, Raja, Salama, Alan D., Schönermarck, Ulf, Segelmark, Mårten, Smith, Lee, Tesař, Vladimír, Wetzels, Jack, Willcocks, Lisa, Windpessl, Martin, Zand, Ladan, Zonozi, Reza and Kronbichler, Andreas (2021) Rituximab in Membranous Nephropathy. Kidney International Reports, 6 (4). pp. 881-893. ISSN 2468-0249

Preview	Text Published Version Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (640kB) | Preview
	Text Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (246kB) | Request a copy

Abstract

Membranous nephropathy is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in a majority of patients changed the management of membranous nephropathy dramatically, and provided a rationale for B cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies including three randomized controlled trials, in which complete and partial remission of proteinuria was achieved in about two thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for membranous nephropathy, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard”.

Item Type:	Journal Article
Keywords:	Membranous nephropathy, nephrotic syndrome, rituximab, B Cells
Faculty:	Faculty of Science & Engineering
SWORD Depositor:	Symplectic User
Depositing User:	Symplectic User
Date Deposited:	14 Jan 2021 16:45
Last Modified:	18 Nov 2021 16:19
URI:	https://arro.anglia.ac.uk/id/eprint/706179

Actions (login required)

Edit Item